ZEB2 is a master switch controlling the tumor-associated macrophage program
Authors:
- 10 April 2025
- journal article
- Published by Elsevier in Cancer Cell
- Vol. 43 (7) , 1227-1241.e11
Abstract
No abstract availableKeywords
Funding Information
- United States - Israel Binational Science Foundation
- Howard Hughes Medical Institute
- Ministero della transizione ecologica (101123436)
- Cancer Research Institute (CRI5226)
- Azrieli Foundation
- European Research Council (101055341-TROJAN-Cell)
- Council for Higher Education
- European Commission
- Lotte and John Hecht Memorial Foundation
- H2020 Marie Skłodowska-Curie Actions (101106452)
- Ministry of Innovation, Science and Technology (1001703362)
- European Molecular Biology Organization (ALTF 723\u20132022)
- Deutsche Forschungsgemeinschaft (259373024 \u2013 TRR 167)
- Weizmann Institute of Science
- Israel Cancer Research Fund
- Israel Science Foundation (1944/22)
This publication has 76 references indexed in Scilit:
- A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancerCancer Cell, 2025
- Neutrophil-activating therapy for the treatment of cancerCancer Cell, 2023
- MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumorsCancer Cell, 2023
- Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratificationCancer Cell, 2021
- Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon CancerCell, 2020
- Comprehensive Integration of Single-Cell DataCell, 2019
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of CancerCell, 2018
- Transcriptional Heterogeneity and Lineage Commitment in Myeloid ProgenitorsCell, 2015
- FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry dataCytometry Part A, 2015
- CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer ModelingCell, 2014